Michael Heffernan assumes the role of Chairman of the Board
Dr. Richard Glickman to step down
Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026
Initiation of BLA submission for detalimogene planned for 2H 2026
Potential FDA approval of detalimogene in 2027
BOSTON & MONTREAL, July 16, 2026--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid ("detalimogene") if approved. Detalimogene is being evaluated in the ongoing, open-label, multi-cohort, Phase 2 LEGEND trial to establish its safety and efficacy in high-risk non-muscle invasive bladder cancer (NMIBC). LEGEND's pivotal cohort (Cohort 1) consists of 125 patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with carcinoma in situ (CIS).
"We are pleased that Michael Heffernan, who has served on our Board since July 2025, will assume the role of Chairman. With a strong track record of guiding companies through development and commercialization, Mike is well positioned to lead our Board as we plan for the potential approval and launch of detalimogene," said Ron Cooper, President and Chief Executive Officer, enGene. "It has been a pleasure to work alongside Dr. Glickman. As a longtime member of the Board, he has played an essential role in guiding enGene's evolution from a research organization to a late clinical-stage company."
Dr. Richard Glickman has served as enGene's Chairman for over 14 years. His expertise was instrumental in supporting the Company's scientific and medical leadership in the development of its unique Dually Derivatized Oligochitosan® (DDX) platform, enabling non-viral gene transfection. His experience in company formation, capital raising and capital markets was also critical in guiding enGene's transition from a seed-stage venture to a publicly listed company. Dr. Glickman continues to serve on the boards of several biotechnology companies.
"With a clinical-stage asset approaching both a key pivotal readout and planned BLA filing in the second half of this year, a potential approval in 2027 and in a strong capital position, enGene is well positioned for a period of meaningful growth," said Michael Heffernan, Chairman of enGene. "I'm excited to step into the role of Chairman and work closely with the Board and management team to advance detalimogene in NMIBC."